Dimensional Fund Advisors
MBRX icon

Dimensional Fund Advisors’s Moleculin Biotech MBRX Stock Holding History

Dimensional Fund Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8
Closed -$16K – 3387
2019
Q4 		$16K Hold
8
– – ﹤0.01% 3375
2019
Q3 		$19K Hold
8
– – ﹤0.01% 3412
2019
Q2 		$21K Hold
8
– – ﹤0.01% 3454
2019
Q1 		$14K Hold
8
– – ﹤0.01% 3442
2018
Q4 		$18K Hold
8
– – ﹤0.01% 3436
2018
Q3 		$28K Hold
8
– – ﹤0.01% 3411
2018
Q2 		$31K Buy
8
+3
+60% +$12.3K ﹤0.01% 3351
2018
Q1 		$19K Buy
+5
New +$21.6K ﹤0.01% 3339

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors's MBRX Position: Q1 2020 in Review

Dimensional Fund Advisors sold out of Moleculin Biotech (MBRX) in Q1 2020, closing a stake of 8 shares — an estimated $16K sold.

Dimensional Fund Advisors first reported a position in MBRX in Q1 2018 and held it in 8 quarters. The position peaked at $31K in Q2 2018. 17 funds tracked by Wall St. Rank hold MBRX as of Q1 2020.

  • Dimensional Fund Advisors reported no remaining Moleculin Biotech position as of Q1 2020 after selling out during the quarter.
  • Dimensional Fund Advisors sold 8 Moleculin Biotech shares in Q1 2020, an estimated $16K.
  • Dimensional Fund Advisors first reported a position in Moleculin Biotech in Q1 2018 and held it in 8 quarters.
  • Dimensional Fund Advisors's Moleculin Biotech position peaked at $31K in Q2 2018.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2020.

Based on Dimensional Fund Advisors's 13F filing for Q1 2020, filed 14 May 2020.